NOVARTIS

NOVARTIS

Displaying 10 out of 65 results

  1. FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

    Novartis to answer US Senate demand for data manipulation details

    Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the ...
  2. FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

    Novartis executive sold shares before drug data manipulation made public

    An unnamed Novartis executive sold 925,400 Swiss francs (US$946,000) worth of shares less than three weeks before the U.S. Food and Drug ...
  3. Swiss drugmaker Novartis' logo is seen in Stein

    Novartis replaces top scientists at Avexis after drug data manipulated

    Novartis said on Wednesday the two top research & development executives at its Avexis unit were no longer at the company after some data from ...
  4. FILE PHOTO: U.S. Senator Grassley speaks to reporters on his way from the Senate floor after a vote

    Senator Grassley seeks info on Novartis's Zolgensma data issues

    U.S. Senate Finance Committee Chairman Chuck Grassley has sought more information from Swiss drugmaker Novartis AG on the reasons for "intentional ...
  5. A Gilead Sciences, Inc. office is shown in Foster City, California

    Medicare to cover expensive cancer cell therapies

    The U.S. Centers for Medicare and Medicaid Services (CMS) on Wednesday said it has finalized a decision to cover expensive cancer cell therapies ...
  6. FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

    Novartis says knew about Zolgensma data problems before US approval

    Drugmaker Novartis on Wednesday acknowledged that there were discrepancies with data it had submitted to regulators for approval of its more than ...
  7. FILE PHOTO: The headquarters of the U.S. Food and Drug Administration is shown in Silver Spring nea

    US FDA says some data testing Novartis' US$2 million gene therapy was manipulated

    The U.S. Food and Drug Administration said on Tuesday that some data from early testing of Novartis' more than US$2 million gene therapy Zolgensma ...
  8. The logo of Swiss drugmaker Novartis is seen outside the company's offices in Athens

    Novartis heart drug fails trial, curbing growth prospects

    Novartis said on Monday a trial for a new use of its Entresto heart drug had failed - calling into questions billions of dollars in hoped for revenue.
  9. FILE PHOTO: Novartis CEO Vas Narasimhan

    Novartis CEO pledges not to sell Sandoz generics unit

    Novartis Chief Executive Vas Narasimhan pledged in an interview published on Saturday not to sell the Swiss drugmaker's generics unit Sandoz amid ...
  10. FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

    Novartis's older MS drug Gilenya wins Chinese approval

    Novartis's Gilenya multiple sclerosis drug has won approval in China, the Swiss drugmaker said on Friday, as the company expands further into the ...